Resultados de procura - Kevin M. Chin

  • Mostrando 1 - 13 Resultados de 13
Limitar resultados
  1. 1
    Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma

    Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma por Ilyssa O. Gordon, Takisha Wade, Kevin M. Chin, Jerome I. Dickstein, Thomas F. Gajewski

    Publicado 2008
    Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  2. 2
    Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

    Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy por Axel Hoos, Ramy Ibrahim, Alan J. Korman, Kald Abdallah, David M. Berman, Vafa Shahabi, Kevin M. Chin, Renzo Canetta, Rachel Humphrey

    Publicado 2010
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

    Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials por Jedd D. Wolchok, Jeffrey S. Weber, Michele Maio, Bart Neyns, Kaan Harmankaya, Kevin M. Chin, L. Cykowski, Veerle de Pril, Rachel Humphrey, Célèste Lebbé

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

    Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study por Susan F. Slovin, Celestia S. Higano, Omid Hamid, Sheela Tejwani, Andrea Harzstark, Joshi J. Alumkal, Howard I. Scher, Kevin M. Chin, Paul Gagnier, M. Brent McHenry, Tomasz M. Beer

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

    Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial por Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish R. Patel, Donald Gravenor, John Nemunaitis, Matthew H. Taylor, Lucjan Wyrwicz, Keun‐Wook Lee, Vijay Kasturi, Kevin M. Chin, Anja von Heydebreck, James L. Gulley

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

    Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b... por James L. Gulley, Arun Rajan, David R. Spigel, Nicholas Iannotti, Jason C. Chandler, Deborah Jean Lee Wong, Joseph W. Leach, W. Jeff Edenfield, Ding Wang, H. Grote, Anja von Heydebreck, Kevin M. Chin, Jean-Marie Cuillerot, Karen Kelly

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

    HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study por Vivek Naranbhai, Mathias Viard, Michael Dean, Stefan Groha, David A. Braun, Chris Labaki, Sachet A. Shukla, Yuko Yuki, Parantu K. Shah, Kevin M. Chin, Megan Wind‐Rotolo, Xinmeng Jasmine Mu, Paul B. Robbins, Alexander Gusev, Toni K. Choueiri, James L. Gulley, Mary Carrington

    Publicado 2021
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

    Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study por Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin M. Chin, James L. Gulley

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study por Luc Dirix, István Takács, Guy Jérusalem, Petros Nikolinakos, Hendrik‐Tobias Arkenau, Andres Forero‐Torres, Ralph V. Boccia, Marc E. Lippman, Robert A. Somer, Martin Šmakal, Leisha A. Emens, Borys Hrinczenko, W. Jeff Edenfield, Jayne S. Gurtler, Anja von Heydebreck, H. Grote, Kevin M. Chin, Erika Hamilton

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma

    Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma por Raffit Hassan, Anish Thomas, John Nemunaitis, Manish R. Patel, Jaafar Bennouna, Franklin L. Chen, Jean‐Pierre Delord, Afshin Dowlati, Samith T. Kochuparambil, Matthew H. Taylor, John D. Powderly, Ulka N. Vaishampayan, Claire F. Verschraegen, H. Grote, Anja von Heydebreck, Kevin M. Chin, James L. Gulley

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial por Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Célèste Lebbé, Gerald P. Linette, Michèle Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Kevin M. Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem

    Publicado 2016
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

    Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial por Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan, Lisa M. Cordes, Arun Rajan, Myrna Rauckhorst, Elizabeth Lamping, Israel Oyelakin, Jennifer L. Marté, Lauren M. Lepone, Renee N. Donahue, Italia Grenga, Jean-Marie Cuillerot, Berend Neuteboom, Anja von Heydebreck, Kevin M. Chin, Jeffrey Schlom, James L. Gulley

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

    Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma por Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Éva Szabó, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin M. Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: